Glycomimetics inc (GLYC)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue

-

-

-

18

20,070

15,027

3,992

15,257

Costs and expenses:
Research and development expense

47,029

40,091

24,100

23,281

25,050

19,571

11,701

9,438

General and administrative expense

14,360

11,413

9,832

8,650

7,805

6,595

2,897

-

Total costs and expenses

61,389

51,504

33,932

31,931

32,855

26,166

14,599

11,622

Selling, general and administrative expense

-

-

-

-

-

-

-

2,183

Loss from operations

-61,389

-51,504

-33,932

-31,913

-12,784

-11,139

-10,606

3,635

Interest income

3,497

3,231

651

103

-

-

-

-

Other income

-

-

-

-

15

18

0

20

Net loss and comprehensive loss

-57,891

-48,273

-33,281

-31,809

-12,769

-11,121

-10,605

3,656

Basic and diluted net loss per common share (in dollars per share)

-1.34

-1.18

-1.13

-1.50

-0.67

-0.60

-8.87

-

Basic and diluted weighted-average number of common shares (in shares)

43,254

41,044

29,395

21,256

19,010

18,452

1,196

-

Earnings Per Share, Basic

-

-

-

-

-

-

-

3.93

Earnings Per Share, Diluted

-

-

-

-

-

-

-

0.33

Weighted Average Number of Shares Outstanding, Basic

-

-

-

-

-

-

-

929

Weighted Average Number of Shares Outstanding, Diluted

-

-

-

-

-

-

-

11,016